BioSpace News Archive

The Company will also host a conference call the same day at 5:00 p.m. ET to discuss these results. Robert Friel, chairman and chief executive officer, and Andy Wilson, senior vice president and chief financial officer, will host the conference call.

DJO announced today that on September 25, 2017 DJO discovered an incident involving the potential disclosure of certain personal information of individuals who received a DJO Global product from the Siena, San Martin or De Lima campuses of St. Rose Dominican Hospital, Las Vegas, Nevada between July 17, 2017 and October 16, 2017.

BioCardia today reported filing a second Investigational Device Exemption with the Food and Drug Administration (FDA) for the CardiAMP Chronic Myocardial Ischemia Trial to treat patients with refractory angina.

Datavant and Verge Genomics today announced a strategic alliance to unlock the value of pharmaceutical datasets to accelerate drug discovery and development.

Both trials commenced in December 2017, in line with KalVista’s previously stated 2017 objectives.

Barwicki Investor Relations is run by Andrew Barwicki, a seasoned veteran with 24 years of marketing and investor relations experience.

Under the terms of the agreement, Nanowear and The Secant Group will have the collective obligation for marketing the technology and associated products.

Rebiotix, announced today its successful first phase of collaboration with CoreBiome to measure the ability of RBX2660 and RBX7455 to rehabilitate the human microbiome impacted by recurrent Clostridium difficile infection.

Jiangsu Hengrui Medicine and Arcutis today announced an exclusive option and license agreement for the development and commercialization of topical applications of Hengrui’s investigational drug, SHR0302.

Dr. Gyuris brings 25 years of scientific leadership experience in the biopharmaceutical industry and will lead all aspects of Trieza’s novel therapeutics discovery and development.